Why Switch?

- Currently used trivalent OPV (tOPV) has three vaccine strains of polio virus (type 1, 2 & 3)
- All circulating wild polio viruses belong to type 1 & 3
- Last reported case of wild polio virus type 2 was in 1999 in India
- Continued use of type 2 strain in vaccine carries the risk of Vaccine Derived Polio Virus infections (VDPV)
- Since 2009, 97% of all VDPVs were due to type 2 virus
- WHO recommends worldwide cessation of type 2 component OPV use

Advantages of bivalent Oral Polio (bOPV) Vaccine

- No type 2 strain
- Preferred oral vaccine in the lead up to complete IPV adaption
- NO interference with immune response to type 1 & 3; lesser number of doses required for herd immunity
- Confers higher seroconversion for poliovirus type 1 & 3
- More effective than tOPV and as good as mOPV
- Recommended for Routine Immunization Activities (RIAs)
- Integrated into the Global Polio Eradication Initiative 2010-2012
Study Results:
Immunogenicity & Safety Proven thro' Bharat Biotech's Pivotal Phase III Clinical Trials on **BIOPOLIO B1/3**

**Immunogenicity**

The most common adverse events reported were fever, cough, cold & vomiting when treated symptomatically. All events were resolved within 24-48 hours.

**Safety**

**BIOPOLIO B1/3 - WHO Prequalified Vaccine**
- More than 2 billion doses sold Worldwide
- Clinically Proven Immunogenicity & Safety
- No shedding of Vaccine Virus

![Image of vaccine bottle]

Adverse Events (%)
- bOPV
- tOPV

4. Data on file

For more information please feel free to email us on info@bharatbiotech.com

Bharat Biotech
Lead Innovation
 Genome Valley Hyderabad - 500 078, T.S., India.
www.bharatbiotech.com